MedTrace Logo

Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).

NCT04898166 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-10-26

Study results available
· View outcomes & findings →

Summary

Coronavirus disease 2019 (COVID-19) can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia. Recent studies show severe outcomes of COVID-19 patients specially in males who suffer from androgenetic alopecia, would be significant and is of particular interest of this study and could help further support the hypothesis that anti-androgen therapy might represents an additional potential intervention against severe COVID-19.

Conditions

Sponsors & Collaborators

  • Syeda Mahanum Ali

    lead OTHER_GOV

Principal Investigators

  • Rabia Ghafoor, MBBS, FCPS, SCE-Derm(MRCP-UK) · Jinnah Postgraduate Medical Centre

  • Syeda Mahanum Ali, MBBS, Postgraduate Trainee · Jinnah Postgraduate Medical Centre

Eligibility

Min Age
20 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04898166 on ClinicalTrials.gov